Gan & Lee Pharmaceuticals. (SHA:603087)

China · Delayed Price · Currency is CNY

65.17

-1.30 (-1.96%)

Jul 13, 2026, 2:25 PM CST

18.49% (1Y)

Market Cap	39.56B +18.3%
Revenue (ttm)	3.95B +13.7%
Net Income	1.02B +23.3%
EPS	1.73 +22.7%
Shares Out	595.20M
PE Ratio	38.37
Forward PE	25.76
Dividend	1.00 (1.50%)
Ex-Dividend Date	May 29, 2026

Volume	10,342,737
Open	66.07
Previous Close	66.47
Day's Range	64.81 - 66.97
52-Week Range	51.51 - 82.25
Beta	0.47
Analysts	Strong Buy
Price Target	72.50 (+11.25%)
Earnings Date	Aug 26, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insu... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 1998

Employees 5,309

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603087

Full Company Profile

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603087 stock is "Strong Buy." The 12-month stock price target is ¥72.50, which is an increase of 11.25% from the latest price.

Price Target

¥72.50

(11.25% upside)

Analyst Consensus: Strong Buy

Stock Forecasts